Mesirow Financial Investment Management Inc. Has $265,000 Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Mesirow Financial Investment Management Inc. lessened its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 52.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,505 shares of the medical equipment provider's stock after selling 2,749 shares during the quarter. Mesirow Financial Investment Management Inc.'s holdings in Zimmer Biomet were worth $265,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in ZBH. AMG National Trust Bank bought a new position in Zimmer Biomet during the 4th quarter worth approximately $3,697,000. Ashton Thomas Private Wealth LLC raised its position in shares of Zimmer Biomet by 106.7% during the 4th quarter. Ashton Thomas Private Wealth LLC now owns 9,062 shares of the medical equipment provider's stock valued at $959,000 after acquiring an additional 4,678 shares in the last quarter. Callan Family Office LLC acquired a new position in Zimmer Biomet in the fourth quarter worth $1,153,000. E Fund Management Co. Ltd. boosted its holdings in Zimmer Biomet by 74.6% in the fourth quarter. E Fund Management Co. Ltd. now owns 3,530 shares of the medical equipment provider's stock worth $373,000 after purchasing an additional 1,508 shares during the period. Finally, Candriam S.C.A. increased its stake in Zimmer Biomet by 24.9% during the fourth quarter. Candriam S.C.A. now owns 21,769 shares of the medical equipment provider's stock valued at $2,299,000 after purchasing an additional 4,336 shares during the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Analysts Set New Price Targets

A number of brokerages have issued reports on ZBH. JPMorgan Chase & Co. raised shares of Zimmer Biomet from a "neutral" rating to an "overweight" rating and raised their target price for the stock from $125.00 to $128.00 in a report on Tuesday, December 17th. Needham & Company LLC reissued a "hold" rating on shares of Zimmer Biomet in a report on Friday, February 7th. Royal Bank of Canada lowered their price objective on Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, February 7th. Raymond James dropped their target price on Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. Finally, JMP Securities reiterated a "market outperform" rating and set a $140.00 price objective on shares of Zimmer Biomet in a research report on Friday, February 7th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, Zimmer Biomet presently has a consensus rating of "Hold" and a consensus price target of $124.15.

Zimmer Biomet Trading Up 3.5 %

ZBH stock traded up $3.60 during mid-day trading on Thursday, reaching $107.63. 2,058,288 shares of the stock traded hands, compared to its average volume of 1,921,787. Zimmer Biomet Holdings, Inc. has a 52-week low of $97.69 and a 52-week high of $133.90. The stock's fifty day moving average is $105.65 and its 200-day moving average is $107.05. The company has a market cap of $21.43 billion, a P/E ratio of 24.19, a P/E/G ratio of 1.95 and a beta of 1.04. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the prior year, the company posted $2.20 earnings per share. As a group, sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.89%. The ex-dividend date of this dividend is Monday, March 31st. Zimmer Biomet's payout ratio is presently 21.57%.

Insiders Place Their Bets

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the firm's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the transaction, the senior vice president now directly owns 8,768 shares in the company, valued at $915,379.20. This trade represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.95% of the company's stock.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.